N NEWAMSTERDAM PHARMA COMPANY
| Market Cap | $3.79B |
| P/E Ratio | — |
| Forward P/E | -24.38 |
| Dividend Yield | — |
| Beta | 0.13 |
| 52W Range | $14.90 - $41.45 |
| # Hedge Funds | 3 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 3 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Lee Ainslie Maverick Capital | 0.71% | $66.45M | 1,894,226 | Add 25.88% |
| Viking Global Investors Viking Global Investors | 0.39% | $147.46M | 4,203,567 | Reduce 35.09% |
| Polen Capital Management Polen Capital Management | 0.00% | $394.00K | 11,239 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 40 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| LANGE LOUIS G | Sale | 446 | $31.23 | $13.93K | 11 Mar 2026 | 11 Mar 2026 |
| LANGE LOUIS G | Sale | 44,173 | $30.41 | $1.34M | 11 Mar 2026 | 11 Mar 2026 |
| Kastelein Johannes Jacob PieterChief Scientific Officer | Sale | 101,409 | $30.29 | $3.07M | 09 Mar 2026 | 05 Mar 2026 |
| LANGE LOUIS G | Sale | 28,186 | $29.41 | $828.95K | 06 Mar 2026 | 06 Mar 2026 |
| Kastelein Johannes Jacob PieterChief Scientific Officer | Sale | 94,124 | $30.32 | $2.85M | 06 Mar 2026 | 05 Mar 2026 |
| Kastelein Johannes Jacob PieterChief Scientific Officer | Sale | 104,467 | $30.30 | $3.17M | 05 Mar 2026 | 05 Mar 2026 |
| Davidson Michael H.Chief Executive Officer | Sale | 443,707 | $33.25 | $14.75M | 02 Mar 2026 | 02 Mar 2026 |
| Davidson Michael H.Chief Executive Officer | Sale | 17,924 | $34.44 | $617.30K | 26 Feb 2026 | 26 Feb 2026 |
| Davidson Michael H.Chief Executive Officer | Sale | 165,408 | $33.63 | $5.56M | 26 Feb 2026 | 26 Feb 2026 |
| Davidson Michael H.Chief Executive Officer | Sale | 1,300 | $36.68 | $47.68K | 25 Feb 2026 | 26 Feb 2026 |
| Davidson Michael H.Chief Executive Officer | Sale | 46,517 | $35.11 | $1.63M | 25 Feb 2026 | 26 Feb 2026 |
| Davidson Michael H.Chief Executive Officer | Sale | 10,436 | $35.96 | $375.28K | 25 Feb 2026 | 26 Feb 2026 |
| Davidson Michael H.Chief Executive Officer | Sale | 3,161 | $36.46 | $115.25K | 24 Feb 2026 | 26 Feb 2026 |
| Davidson Michael H.Chief Executive Officer | Sale | 61,547 | $36.13 | $2.22M | 24 Feb 2026 | 26 Feb 2026 |
| Kastelein Johannes Jacob PieterChief Scientific Officer | Sale | 30,789 | $35.46 | $1.09M | 20 Feb 2026 | 24 Feb 2026 |
| Kastelein Johannes Jacob PieterChief Scientific Officer | Sale | 14,692 | $35.00 | $514.22K | 20 Feb 2026 | 24 Feb 2026 |
| Kooij Louise FrederikaChief Accounting Officer | Sale | 32,612 | $31.80 | $1.04M | 28 Jan 2026 | 29 Jan 2026 |
| Kooij Louise FrederikaChief Accounting Officer | Sale | 39,816 | $32.62 | $1.30M | 27 Jan 2026 | 29 Jan 2026 |
| Kooij Louise FrederikaChief Accounting Officer | Sale | 34,091 | $32.77 | $1.12M | 26 Jan 2026 | 27 Jan 2026 |
| Kooij Louise FrederikaChief Accounting Officer | Sale | 309 | $33.45 | $10.34K | 26 Jan 2026 | 27 Jan 2026 |
| Kooij Louise FrederikaChief Accounting Officer | Sale | 12,767 | $34.37 | $438.80K | 23 Jan 2026 | 27 Jan 2026 |
| Kooij Louise FrederikaChief Accounting Officer | Sale | 25,405 | $33.44 | $849.54K | 23 Jan 2026 | 27 Jan 2026 |
| Somaiya Mayur IanChief Financial Officer | Sale | 24,362 | $33.80 | $823.44K | 21 Jan 2026 | 22 Jan 2026 |
| Somaiya Mayur IanChief Financial Officer | Sale | 15,422 | $33.25 | $512.78K | 21 Jan 2026 | 22 Jan 2026 |
| Somaiya Mayur IanChief Financial Officer | Sale | 19,604 | $32.38 | $634.78K | 20 Jan 2026 | 22 Jan 2026 |
| Somaiya Mayur IanChief Financial Officer | Sale | 900 | $30.64 | $27.58K | 20 Jan 2026 | 22 Jan 2026 |
| Somaiya Mayur IanChief Financial Officer | Sale | 39,712 | $31.78 | $1.26M | 20 Jan 2026 | 22 Jan 2026 |
| Davidson Michael H.Chief Executive Officer | Sale | 11,582 | — | — | 07 Jan 2026 | 09 Jan 2026 |
| Kooij Louise FrederikaChief Accounting Officer | Sale | 2,647 | $33.25 | $88.01K | 05 Jan 2026 | 07 Jan 2026 |
| Somaiya Mayur IanChief Financial Officer | Sale | 5,118 | $33.25 | $170.17K | 05 Jan 2026 | 07 Jan 2026 |
| Kastelein Johannes Jacob PieterChief Scientific Officer | Sale | 6,000 | $33.25 | $199.50K | 05 Jan 2026 | 07 Jan 2026 |
| Mayur Ian SomaiyaChief Financial Officer | Sale | 5,118 | $33.25 | $170.17K | 05 Jan 2026 | 07 Jan 2026 |
| Louise Frederika KooijChief Accounting Officer | Sale | 2,647 | $33.25 | $88.01K | 05 Jan 2026 | 07 Jan 2026 |
| Johannes Jacob Pieter KasteleinChief Scientific Officer | Sale | 6,000 | $33.25 | $199.50K | 05 Jan 2026 | 07 Jan 2026 |
| Kooij Louise FrederikaChief Accounting Officer | Sale | 43,872 | $35.30 | $1.55M | 26 Dec 2025 | 29 Dec 2025 |
| Louise Frederika KooijChief Accounting Officer | Sale | 43,872 | $35.30 | $1.55M | 26 Dec 2025 | 29 Dec 2025 |
| Kooij Louise FrederikaChief Accounting Officer | Sale | 26,011 | $35.68 | $928.07K | 24 Dec 2025 | 29 Dec 2025 |
| Louise Frederika KooijChief Accounting Officer | Sale | 26,011 | $35.68 | $928.07K | 24 Dec 2025 | 29 Dec 2025 |
| Kooij Louise FrederikaChief Accounting Officer | Sale | 75,117 | $36.21 | $2.72M | 23 Dec 2025 | 29 Dec 2025 |
| Louise Frederika KooijChief Accounting Officer | Sale | 75,117 | $36.21 | $2.72M | 23 Dec 2025 | 29 Dec 2025 |
Frequently Asked Questions
What is NAMS stock price today?
NEWAMSTERDAM PHARMA COMPANY (NAMS) is currently trading at $32.99. The stock has a 52-week range of $14.90 to $41.45 and a market capitalization of $3.79B.
Is NAMS a good stock to buy in 2026?
NEWAMSTERDAM PHARMA COMPANY has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +83.3%. 3 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling NAMS stock?
There have been 40 insider transactions for NAMS in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has NAMS stock performed over the past year?
NEWAMSTERDAM PHARMA COMPANY (NAMS) has returned +83.3% over the past 12 months. The stock traded between $14.90 and $41.45 during this period, and is currently at $32.99.
Which hedge funds own NAMS (NEWAMSTERDAM PHARMA COMPANY)?
3 tracked hedge funds currently hold NAMS in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is NAMS's market cap and valuation?
NEWAMSTERDAM PHARMA COMPANY (NAMS) has a market capitalization of $3.79B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is NAMS's revenue and profitability?
NEWAMSTERDAM PHARMA COMPANY reported revenue of $22.50M with net income of N/A and a profit margin of N/A. The stock has a beta of 0.13.
What sector is NAMS in and who are its biggest institutional holders?
NEWAMSTERDAM PHARMA COMPANY (NAMS) operates in the Healthcare sector. It is held by 3 tracked hedge funds. See the ownership table above for the complete list.